Switch theme
Sign up to access all valuation multiples
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company’s activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.
2017
n/a
LTM Revenue $72.9M
LTM EBITDA $8.5M
$61.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Labiana Health has a last 12-month revenue (LTM) of $72.9M and a last 12-month EBITDA of $8.5M.
In the most recent fiscal year, Labiana Health achieved revenue of $65.7M and an EBITDA of $3.5M.
Labiana Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Labiana Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $72.9M | XXX | $65.7M | XXX | XXX | XXX |
| Gross Profit | $72.9M | XXX | $38.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $8.5M | XXX | $3.5M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| EBIT | $2.9M | XXX | -$2.1M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | -3% | XXX | XXX | XXX |
| Net Profit | $43K | XXX | -$5.0M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $41.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Labiana Health's stock price is EUR 3 (or $4).
Labiana Health has current market cap of EUR 24.3M (or $27.3M), and EV of EUR 54.9M (or $61.6M).
See Labiana Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61.6M | $27.3M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Labiana Health has market cap of $27.3M and EV of $61.6M.
Labiana Health's trades at 0.9x EV/Revenue multiple, and 17.7x EV/EBITDA.
Equity research analysts estimate Labiana Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Labiana Health has a P/E ratio of 639.9x.
See valuation multiples for Labiana Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $27.3M | XXX | $27.3M | XXX | XXX | XXX |
| EV (current) | $61.6M | XXX | $61.6M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.2x | XXX | 17.7x | XXX | XXX | XXX |
| EV/EBIT | 21.2x | XXX | -29.7x | XXX | XXX | XXX |
| EV/Gross Profit | 0.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 639.9x | XXX | -5.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -11.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLabiana Health's last 12 month revenue growth is 14%
Labiana Health's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Labiana Health's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Labiana Health's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Labiana Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Labiana Health acquired XXX companies to date.
Last acquisition by Labiana Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Labiana Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Labiana Health founded? | Labiana Health was founded in 2017. |
| Where is Labiana Health headquartered? | Labiana Health is headquartered in Spain. |
| Is Labiana Health publicy listed? | Yes, Labiana Health is a public company listed on MAD. |
| What is the stock symbol of Labiana Health? | Labiana Health trades under LAB ticker. |
| When did Labiana Health go public? | Labiana Health went public in 2022. |
| Who are competitors of Labiana Health? | Similar companies to Labiana Health include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Labiana Health? | Labiana Health's current market cap is $27.3M |
| What is the current revenue of Labiana Health? | Labiana Health's last 12 months revenue is $72.9M. |
| What is the current revenue growth of Labiana Health? | Labiana Health revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Labiana Health? | Current revenue multiple of Labiana Health is 0.8x. |
| Is Labiana Health profitable? | Yes, Labiana Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Labiana Health? | Labiana Health's last 12 months EBITDA is $8.5M. |
| What is Labiana Health's EBITDA margin? | Labiana Health's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Labiana Health? | Current EBITDA multiple of Labiana Health is 7.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
